Infusion of Furosemide to Improve Diuretic Efficiency in Acute Heart Failure

Recruiting Phase 4 Interventional Study
Acute Heart Failure Volume Overload
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 4
Study type
Interventional
Purpose
Treatment
Participants needed
436 (estimated)
Sponsor
University of Aarhus · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Acute heart failure is a condition where the heart suddenly cannot pump blood well enough for the body's needs. Many people admitted to the hospital with acute heart failure have too much fluid in the body. This can cause shortness of breath, swelling, and the need for treatment with water-removing medicine. Furosemide is a commonly used water-removing medicine that is given into a vein to treat …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Clinical diagnosis of acute heart failure with volume overload * At least 1 sign of volume overload * Anticipated intravenous furosemide treatment for at least 3 days * Age 18 years or older Exclusion Criteria: * Shock * Patient requiring treatment with inotropes or vasopres…
Contacts

Esben Merrild, MD

+4522996026

esbenmerrild@clin.au.dk

CONTACT